COVID-19: Pre-clinical development of a therapeutic to treat Acute Respiratory Distress Syndrome in COVID-19
$3,489,024.00
Grant Value
2021-22
Fiscal Year
Description
Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leakage in Acute Respiratory Distress Syndrome.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Mannin Research Inc
Location
Toronto, ON M4M 1E4
Agreement Details
Number: 967028
Reference: 172-2021-2022-Q4-967028
Timeline
Start: Feb. 9, 2021
End: Dec. 2, 2022
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share